| 51 |
21212155 | Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. | 2011 Jul |
1 |
| 52 |
21345796 | B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. | 2011 Apr 15 |
1 |
| 53 |
21392074 | Population pharmacokinetic analysis of sorafenib in patients with solid tumours. | 2011 Aug |
1 |
| 54 |
21427706 | Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. | 2011 Jun |
1 |
| 55 |
21844014 | Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. | 2011 Nov 15 |
2 |
| 56 |
21900390 | Role of BRAF in thyroid oncogenesis. | 2011 Dec 15 |
1 |
| 57 |
21903858 | BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. | 2011 Dec |
1 |
| 58 |
21929745 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. | 2011 Sep 19 |
1 |
| 59 |
22174910 | Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. | 2011 |
1 |
| 60 |
22179180 | Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. | 2011 Dec |
2 |
| 61 |
22212931 | Signaling pathways in hepatocellular carcinoma. | 2011 |
1 |
| 62 |
19935794 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. | 2010 Jan 5 |
1 |
| 63 |
20337484 | Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. | 2010 May 4 |
2 |
| 64 |
20414921 | Prospects for non-immunological molecular therapeutics in melanoma. | 2010 Jan-Mar |
1 |
| 65 |
20525481 | [New therapies targeting the genetic mutations responsible for different types of melanoma]. | 2010 Jun |
1 |
| 66 |
20571072 | Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. | 2010 Jul |
1 |
| 67 |
20621496 | The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | 2010 Aug 1 |
1 |
| 68 |
20658715 | Targeted treatment for metastatic renal cell carcinoma and immune regulation. | 2010 Apr-Jun |
1 |
| 69 |
20672370 | Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. | 2010 Dec 1 |
1 |
| 70 |
20726440 | Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. | 2010 |
1 |
| 71 |
20810616 | Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. | 2010 Nov |
2 |
| 72 |
18794803 | CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. | 2009 Jan 8 |
1 |
| 73 |
19209155 | Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. | 2009 Mar |
1 |
| 74 |
19228077 | Sorafenib: a review of its use in advanced hepatocellular carcinoma. | 2009 |
2 |
| 75 |
19542731 | [Sorafenib(Nexavar)]. | 2009 Jun |
4 |
| 76 |
19572644 | Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. | 2009 Sep 23 |
1 |
| 77 |
19638574 | Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | 2009 Aug 15 |
3 |
| 78 |
19672141 | Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. | 2009 Jul-Aug |
1 |
| 79 |
19878585 | Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. | 2009 Oct 31 |
6 |
| 80 |
19917255 | C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). | 2009 Nov 13 |
1 |
| 81 |
20038816 | Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. | 2009 Dec |
1 |
| 82 |
18192256 | Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. | 2008 Jan 15 |
1 |
| 83 |
18413802 | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | 2008 Apr |
1 |
| 84 |
18596389 | Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. | 2008 Jul |
1 |
| 85 |
18616678 | Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. | 2008 Sep |
1 |
| 86 |
18775988 | Characterization of Ser338 phosphorylation for Raf-1 activation. | 2008 Nov 14 |
1 |
| 87 |
19001320 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | 2008 Dec 10 |
1 |
| 88 |
17229632 | The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. | 2007 Jan |
3 |
| 89 |
17266941 | Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. | 2007 May 1 |
2 |
| 90 |
17296815 | Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. | 2007 Feb |
1 |
| 91 |
17341847 | Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. | 2007 |
1 |
| 92 |
17409425 | Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. | 2007 Apr 1 |
1 |
| 93 |
17591826 | Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. | 2007 Jun |
1 |
| 94 |
17664273 | Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. | 2007 Oct 5 |
1 |
| 95 |
17909054 | Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. | 2007 Oct 1 |
2 |
| 96 |
18473997 | Therapeutic strategies for targeting BRAF in human cancer. | 2007 May |
1 |
| 97 |
16757355 | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. | 2006 |
1 |
| 98 |
16890795 | Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. | 2006 Aug |
1 |
| 99 |
15819587 | Improving outcomes in advanced malignant melanoma: update on systemic therapy. | 2005 |
2 |
| 100 |
16255777 | Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. | 2005 Oct 28 |
4 |